- HSBC expects stable Q4FY26 for hospital stocks with seasonal elective procedure growth
- Apollo Hospitals remains top pick with Buy rating and target price raised to Rs 9,000
- Other hospital stocks like Max, Aster, KIMS, and Rainbow retain Buy with revised targets
HSBC expects a stable Q4FY26 for listed hospital players, supported by a seasonal pick-up in elective procedures after a typically weak December quarter. While growth visibility remains intact, analysts flag margin pressures from ongoing capex and new unit additions as a key monitorable for the sector. The overall tone remains constructive, with most major hospital stocks retaining positive ratings, led by Apollo Hospitals.
Apollo Hospitals continues to be the top sector pick, with HSBC maintaining a Buy rating and raising the target price to Rs 9,000 from Rs 8,750. HSBC expects the company to sustain healthy growth trends, aided by strong occupancy, case mix improvement, and scale benefits. The focus also remains on Apollo's expanding digital ecosystem and capacity additions, which are seen driving long-term value despite near-term cost pressures.
Across the sector, HSBC largely reiterated positive stances while tweaking target prices upward, reflecting confidence in structural demand.
Max Healthcare: Maintained Buy with a target price of Rs 1,125, supported by steady operational performance.
Aster DM Healthcare: Buy maintained; target price raised sharply to Rs 755 from Rs 635, indicating improved earnings visibility.
KIMS: Retains Buy with a revised target of Rs 780, factoring in steady growth and manageable margin impact.
Rainbow Children's Hospitals: Maintained Buy with a target price of Rs 1,400, backed by consistent pediatric and maternity demand trends.
Margin Pressures Remain Key Overhang
Despite steady revenue growth, EBITDA margins are expected to remain under pressure in the near term due to the costs associated with new hospitals and capacity expansion. New units typically take time to stabilize, leading to initial drag on profitability, even as they contribute to revenue growth. This trend is expected across players like KIMS, Rainbow, and others expanding aggressively.
Not all stocks are equally preferred.
Global Health (Medanta): Maintained Hold, with a marginal target price increase to Rs 1,120, reflecting balanced risk-reward.
Narayana Hrudayalaya: Retained at Reduce, with a slightly higher target price of Rs 1,630, as integration-related challenges and earnings visibility weigh on sentiment.
HSBC remains positive on the long-term structural story for India's hospital sector, driven by rising healthcare demand, increasing insurance penetration, and expansion into tier-2/3 cities.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
